Hypertrophic and Hypertensive Hypertrophic Cardiomyopathy—A True Association?

Papadopoulos, Dimitris P.; Papademetriou, Vasilios

doi:10.1177/0003319709331391

Cited by 5 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HTN can also cause myocardial hypertrophy, which is characterized by concentric hypertrophy. Hemodynamic overloading and the subsequent proliferation of sarcomere protein may be the main causes of myocardial hypertrophy in patients with HTN 3,4 . The main differences between HTN with concentric LVH and HCM include systolic anterior motion (SAM), early diastolic time intervals, and differences in long-axis systolic and diastolic left ventricular functions 3 .…”

mentioning

confidence: 99%

Retrospective analysis of clinical phenotype and prognosis of hypertrophic cardiomyopathy complicated with hypertension

Luo

Chen

Zhang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

We here studied the clinical features, cardiac structure, and functional changes and prognosis of hypertrophic cardiomyopathy (HCM) patients with hypertension (HTN). A total of 90 HCM patients with HTN and 172 patients without HTN were divided into a hypertensive group and non-hypertensive group. the clinical characteristics, cardiac structure and function, and prognosis of the two groups were compared. our study found that HcM patients with Htn had fewer syncope events in their medical histories (8% vs. 22%, P < 0.01) and sudden deaths in the family (3% vs. 10%, P < 0.05). The prevalence of apical hypertrophy (18% vs. 7%, P < 0.01) and midventricular obstruction (26% vs. 15%, P < 0.05) was higher in the Htn group. Besides, simple HcM patients had more pathogenic gene mutations, while those with HTN were more likely to have mutations of uncertain clinical significance (64% vs. 24%, P < 0.05). Evaluation of 5-year survival rate showed a trend for a worse prognosis in HCM patients with HTN, but the results were not statistically insignificant (P = 0.065). In conclusion, we found that the clinical phenotypes of HCM patients with HTN differed from those of patients with HCM alone, suggesting that Htn may play a pathogenic role in the pathogenesis of hypertensive hypertrophic cardiomyopathy patients.

show abstract

mentioning

confidence: 99%

Retrospective analysis of clinical phenotype and prognosis of hypertrophic cardiomyopathy complicated with hypertension

Luo

Chen

Zhang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Systemic hypertension and HCM are important causes of LV hypertrophy (LVH). The frequency of coexistence of HCM and hypertension increases with age and poses significant diagnostic and management challenges 3,4 . It is unclear to what extent one disease affects the cardiac phenotypic expression and clinical outcome of the other.…”

mentioning

confidence: 99%

“…The frequency of coexistence of HCM and hypertension increases with age and poses significant diagnostic and management challenges. 3,4 It is unclear to what extent one disease affects the cardiac phenotypic expression and clinical outcome of the other. The purpose of this study was to compare the echocardiographic and clinical outcome of patients with HCM and with and without systemic hypertension.…”

mentioning

confidence: 99%

The Frequency and Functional Impact of Overlapping Hypertension on Hypertrophic Cardiomyopathy: A Single‐Center Experience

Aslam

Haque

Foody

et al. 2010

J of Clinical Hypertension

View full text Add to dashboard Cite

Between 1995 and 2005, 196 adults with hypertrophic cardiomyopathy (HCM) were evaluated. Among these, 122 (62%, group 1) patients also had systemic hypertension. The clinical presentation, management, outcome, and echocardiographic findings of these patients were compared with 74 (38%, group 2) patients without systemic hypertension. Patients in group 1 were older at the time of HCM diagnosis and had a higher prevalence of diabetes (28% vs 9%; P=.02) and coronary artery disease (40% vs 25%; P=.03). In addition, echocardiography showed a significantly higher prevalence of systolic anterior motion of the anterior mitral valve in association with dynamic left ventricular outflow obstruction (52% vs 19%; P=.02) and mitral annular calcification (27% vs 13%; P=.03) in group 1 patients. Left ventricular wall thickness (17 mm vs 19 mm), end-diastolic diameter (42 mm vs 42 mm), resting outflow tract gradient >30 mm Hg (17% vs 16%), and ejection fraction (65% vs 64%) were similar in the two groups. HCM frequently coexists with systemic hypertension in the adult population. Presence of systemic hypertension in HCM patients is associated with older age and higher risk of diabetes, coronary artery disease, and noncardiac death.

show abstract

“…Hypertension-induced increases in sustained pressure load cause increased left ventricular wall stress and thereby stimulate myocardial hypertrophy (3). Wall stress stimulates sarcomeres to grow in a parallel pattern by increasing protein synthesis, which increases myocyte width in response to increased afterload (19). Cardiac hypertrophy, therefore, is a compensatory response to increased wall stress.…”

Section: Discussionmentioning

confidence: 99%

Expression and distribution of Src in the nucleus of myocytes in cardiac hypertrophy

Chen

et al. 2013

International Journal of Molecular Medicine

View full text Add to dashboard Cite

The Src kinase is involved in signaling events leading to cardiac hypertrophy. The exact effects of tyrosine phosphorylation and subnuclear distribution on cardiac hypertrophy and failure remain to be investigated. In this study, we examined the intranuclear expression and distribution of c-Src, Src phosphorylated at tyrosine 529 (Src[pY529]), Src phosphorylated at tyrosine 418 (Src[pY418]) and Src phosphorylated at tyrosine 215 (Src[pY215]) in the myocardial nuclei of the left ventricle (LV) from 2-, 6-, 12- and 18-month-old spontaneously hypertensive heart failure (SHHF) rats and age-matched Wistar-Kyoto (WKY) rats as normotensive controls by western blot analysis, immunofluorescent labeling and immunoprecipitation. Cellular Src (c-Src) expression in the myocardial nuclei of the LV of the 2-, 6-, 12- and 18-month-old SHHF rats was not significantly different from that in the myocardial nuclei of the LV of the age-matched WKY rats. Although there were no significant differences observed between the levels of Src[pY529] and Src[pY418] in the myocardial nuclei of the LV of the 2-month-old SHHF and WKY rats, the expression of Src[pY529] significantly decreased, while that of Src[pY418] significantly increased in the myocardial nuclei of the LV of the 6-, 12- and 18-month-old SHHF rats compared to the age-matched WKY controls. Furthermore, as demonstrated by double labeling with antibodies against fibrillarin and Src-associated in mitosis 68 kDa (Sam68), c-Src was co-localized with both Sam68 and fibrillarin in the nuclei; Src[pY529] co-localized with fibrillarin, but Src[pY418] co-localized with Sam68. The results from the present study suggest that the dephosphorylation of Src tyrosine kinase 529, the phosphorylation of tyrosine 418 and their subnuclear redistribution are involved in endonuclear signal transduction in cardiac myocytes, which regulates the development and progression of LV eccentric hypertrophy induced by hypertension.

show abstract

Hypertrophic and Hypertensive Hypertrophic Cardiomyopathy—A True Association?

Cited by 5 publications

References 28 publications

Retrospective analysis of clinical phenotype and prognosis of hypertrophic cardiomyopathy complicated with hypertension

Retrospective analysis of clinical phenotype and prognosis of hypertrophic cardiomyopathy complicated with hypertension

The Frequency and Functional Impact of Overlapping Hypertension on Hypertrophic Cardiomyopathy: A Single‐Center Experience

Expression and distribution of Src in the nucleus of myocytes in cardiac hypertrophy

Contact Info

Product

Resources

About